初诊胶质母细胞瘤血脑屏障开放后重复超选择性动脉内贝伐珠单抗的I/II期临床试验
该I/II期研究评估初诊胶质母细胞瘤患者在血脑屏障开放后重复行超选择性动脉内贝伐珠单抗灌注的安全性与疗效。23例患者接受15 mg/kg贝伐珠单抗于术后第30±7、120±7、210±7天给药并联合标准放化疗,中位无进展生存期11.5个月,中位总生存期23.1个月。
要点
- 血脑屏障开放后重复动脉内贝伐珠单抗联合标准放化疗显示鼓舞人心的无进展生存期与总生存期。
- 中位无进展生存期11.5个月,中位总生存期23.1个月。
- 结果支持开展III期试验比较该方案与单纯Stupp方案。
核心结论
- 血脑屏障开放后重复动脉内贝伐珠单抗给药在无进展生存期和总生存期方面显示鼓舞人心的结果。
- 需要III期试验确定重复动脉内贝伐珠单抗联合Stupp方案是否优于单纯Stupp方案。
研究设计与样本
- I/II期临床试验,共纳入23例初诊胶质母细胞瘤患者,中位年龄60.5岁(SD=12.6;24.7-78.3)。
- 手术日为第0天,评估患者在第30±7、120±7、210±7天接受血脑屏障开放后超选择性动脉内贝伐珠单抗15 mg/kg,并联合6周标准放化疗。
- 采用神经肿瘤反应评估标准及Kaplan-Meier乘积极限法评估无进展生存期和总生存期。
主要发现
- 异柠檬酸脱氢酶突变见于1/23(4%)患者。
- MGMT状态在11/23患者中可得(7例未甲基化;3例甲基化;1例不确定)。
- 中位肿瘤体积24.0 cm3(SD=31.1,1.7-48.3 cm3)。
- 中位无进展生存期11.5个月(95%CI 7.7-25.9),6、12、24和60个月无进展生存率估计分别为91.3%(95%CI 69.5-97.8)、47.4%(26.3-65.9)、32.5%(14.4-52.2)和5.4%(0.4-21.8)。
- 中位总生存期23.1个月(95%CI 12.2-36.9),12、24和36个月总生存率分别为77.3%(95%CI 53.6-89.9)、45.0%(22.3-65.3)和32.1%(12.5-53.8)。
临床怎么用
- 对于初诊胶质母细胞瘤,可考虑在血脑屏障开放后重复行动脉内贝伐珠单抗灌注并联合标准放化疗,但尚需III期试验验证其相对Stupp方案的优效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pre-clinical evidence suggests bevacizumab (BV) depletes the GBM peri-vascular cancer-stem cell niche. This phase I/II study assesses the safety and efficacy of repeated doses of superselective intra-arterial cerebral infusion (SIACI) of BV after blood-brain barrier disruption (BBBD). METHODS: Date of surgery was day 0. Evaluated patients received repeated SIACI bevacizumab (15 mg/kg) with BBBD at days 30 ± 7, 120 ± 7, and 210 ± 7 along with 6 weeks of standard chemoradiation. Response assessment in neuro-oncology criteria and the Kaplan-Meier product-limit method was used to evaluate progression free and overall survival (PFS and OS, respectively). RESULTS: Twenty-three patients with a median age of 60.5 years (SD = 12.6; 24.7-78.3) were included. Isocitrate dehydrogenase mutation was found in 1/23 (4%) patients. MGMT status was available for 11/23 patients (7 unmethylated; 3 methylated; 1 inconclusive). Median tumor volume was 24.0 cm3 (SD = 31.1, 1.7-48.3 cm3). Median PFS was 11.5 months (95% CI 7.7-25.9) with 6, 12, 24 and 60 month PFS estimated to be 91.3% (95% CI 69.5-97.8), 47.4% (26.3-65.9), 32.5% (14.4-52.2) and 5.4% (0.4-21.8), respectively. Median OS was 23.1 months (95% CI 12.2-36.9) with 12, 24, and 36 month OS as 77.3% (95% CI 53.6-89.9), 45.0% (22.3-65.3) and 32.1% (12.5-53.8), respectively. CONCLUSIONS: Repeated dosing of IA BV after BBBD offers an encouraging outcome in terms of PFS and OS. Phase III trials are warranted to determine whether repeated IA BV combined with Stupp protocol is superior to Stupp protocol alone for newly diagnosed GBM.
引用
- Patel NV, Wong T, Fralin SR, et al. Repeated superselective intraarterial bevacizumab after blood brain barrier disruption for newly diagnosed glioblastoma: a phase I/II clinical trial. J Neurooncol. 2021. PMID: 34601657. doi:10.1007/s11060-021-03851-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。